1. Market Research
  2. > Cardiovascular Inflammation - Pipeline Review, H2 2013

Cardiovascular Inflammation - Pipeline Review, H2 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 37 pages

Cardiovascular Inflammation - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Cardiovascular Inflammation - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Cardiovascular Inflammation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiovascular Inflammation. Cardiovascular Inflammation - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cardiovascular Inflammation.
- A review of the Cardiovascular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cardiovascular Inflammation pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cardiovascular Inflammation.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cardiovascular Inflammation pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Cardiovascular Inflammation - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cardiovascular Inflammation Overview 6
Therapeutics Development 7
Pipeline Products for Cardiovascular Inflammation - Overview 7
Pipeline Products for Cardiovascular Inflammation - Comparative Analysis 8
Cardiovascular Inflammation - Therapeutics under Development by Companies 9
Cardiovascular Inflammation - Therapeutics under Investigation by Universities/Institutes 10
Cardiovascular Inflammation - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Cardiovascular Inflammation - Products under Development by Companies 13
Cardiovascular Inflammation - Products under Investigation by Universities/Institutes 14
Cardiovascular Inflammation - Companies Involved in Therapeutics Development 15
Genfit SA 15
Priaxon AG 16
Ampio Pharmaceuticals, Inc. 17
NovelMed Therapeutics, Inc. 18
Cardiovascular Inflammation - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Assessment by Therapeutic Class 27
Drug Profiles 29
trehalose - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
DMI-4983 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Drug For Inflammation In Ischemia Reperfusion Injury - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
SAVX-1 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
FP-1115 - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Cardiovascular Inflammation - Dormant Projects 34
Cardiovascular Inflammation - Discontinued Products 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37



List of Tables

Number of Products under Development for Cardiovascular Inflammation, H2 2013 7
Number of Products under Development for Cardiovascular Inflammation - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Stage Development, H2 2013 12
Products under Development by Companies, H2 2013 13
Products under Investigation by Universities/Institutes, H2 2013 14
Cardiovascular Inflammation - Pipeline by Genfit SA, H2 2013 15
Cardiovascular Inflammation - Pipeline by Priaxon AG, H2 2013 16
Cardiovascular Inflammation - Pipeline by Ampio Pharmaceuticals, Inc., H2 2013 17
Cardiovascular Inflammation - Pipeline by NovelMed Therapeutics, Inc., H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Stage and Target, H2 2013 21
Number of Products by Stage and Mechanism of Action, H2 2013 23
Number of Products by Stage and Route of Administration, H2 2013 24
Number of Products by Stage and Molecule Type, H2 2013 26
Number of Products by Stage and Therapeutic Class, H2 2013 28
Cardiovascular Inflammation - Dormant Projects, H2 2013 34
Cardiovascular Inflammation - Discontinued Products, H2 2013 35



List of Figures

Number of Products under Development for Cardiovascular Inflammation, H2 2013 7
Number of Products under Development for Cardiovascular Inflammation - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Early Stage Products, H2 2013 12
Assessment by Monotherapy Products, H2 2013 19
Number of Products by Top 10 Target, H2 2013 20
Number of Products by Stage and Top 10 Target, H2 2013 21
Number of Products by Top 10 Mechanism of Action, H2 2013 22
Number of Products by Stage and Top 10 Mechanism of Action, H2 2013 23
Number of Products by Top 10 Molecule Type, H2 2013 25
Number of Products by Stage and Top 10 Molecule Type, H2 2013 26
Number of Products by Top 10 Therapeutic Class, H2 2013 27
Number of Products by Stage and Top 10 Therapeutic Class, H2 2013 28



Companies Mentioned

Genfit SA
Priaxon AG
Ampio Pharmaceuticals, Inc.
NovelMed Therapeutics, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.